Engflag

Medrin

Quick links to important sections

Medrin

Medrin_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Medrin

Property Description
Active Ingredients Cefradine, Embramine, Embramine Teoclate
Form Oral Solid Dosage Form (e.g., Tablet/Capsule)
Pharmacological Class β-Lactam Antibiotic and Histamine H1 Antagonist
General Purpose Simultaneous treatment of bacterial infection and associated symptoms
Origin Semisynthetic (Cefradine) and Synthetic (Embramine components)

Medrin is a unique fixed-dose combination (FDC) pharmaceutical preparation designed for oral administration, simultaneously delivering an antibiotic and an antihistamine, a formulation that is clinically recognized for addressing conditions where infection and symptomatic relief are both required. The drug is officially categorized by its components as both a β-Lactam Antibiotic and a Histamine H1 Antagonist. This structure allows for a single product to manage underlying bacterial infection while mitigating specific physiological discomfort.

Medrin: Definition and Pharmaceutical Classification

Medrin is defined as an FDC medicine, typically provided in an oral solid dosage form. This necessitates that the medicine falls under two distinct pharmacological groups: the β-Lactam antibiotic class, specifically a first-generation cephalosporin, which targets bacterial pathogens, and the Histamine H1 Antagonist class, which addresses allergic and neurogenic responses. As the antibiotic component is generally considered a Prescription-only (Rx) medicine, the entire FDC formulation would require a prescription.

Composition and Origin of Active Ingredients

The three active ingredients in Medrin are Cefradine, Embramine, and Embramine Teoclate. Cefradine is a semisynthetic cephalosporin providing the core antibacterial action. The symptomatic function is supplied by the synthetic compounds Embramine and Embramine Teoclate. The unique inclusion of Embramine Teoclate (a salt form) is a key feature, as teoclate salts are often selected in pharmacological development to influence factors such as stability or anti-nausea activity.

General Purpose of the Combined Action

The general purpose of this combined drug is to manage two separate physiological objectives efficiently. The formulation achieves this by providing the essential antibacterial action via Cefradine while concurrently supplying the antiallergic and anti-vertigo properties of the Embramine components, which function by blocking histamine release. This dual-action design provides a comprehensive benefit, offering treatment for the pathogenic source alongside relief for symptoms commonly associated with a systemic illness, such as allergic symptoms or related nausea.

Regulatory References

  1. β-Lactam Antibiotic
  2. Histamine H1 Antagonist
  3. β-Lactam antibiotic
  4. active ingredients
  5. INN
  6. semisynthetic cephalosporin
  7. antiallergic

What side effects are possible with Medrin?

Possible Side Effects and Safety Information for Medrin

Official regulatory documents from agencies like the FDA and EMA establish the comprehensive safety profile for Medrin, which details known adverse reactions and necessary risk minimization strategies.

Adverse reactions are categorized by frequency (e.g., Common, Uncommon, Rare) and System-Organ Class (SOC) to provide a structured overview of potential risks. Frequently reported adverse events may involve Gastrointestinal disorders (such as nausea or constipation), Nervous system disorders (including headache or dizziness), and General disorders and administration site conditions.

Clinically Significant and Serious Adverse Reactions

Regulatory agencies define serious adverse reactions as those that may result in death, hospitalization, persistent disability, or are life-threatening. Official safety warnings address events like Serotonin Syndrome, which can occur, especially when Medrin is used concomitantly with other serotonergic agents. Other significant risks include elevations in blood pressure and heart rate, hepatotoxicity (liver damage), and risk of abnormal bleeding, requiring caution with concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin.

Adverse Reaction Category Examples of Reported Effects (by SOC)
Cardiovascular Hypertension, palpitations, increased heart rate
Gastrointestinal Nausea, constipation, dry mouth, vomiting
Nervous System Headache, dizziness, insomnia, seizures (rarely)
General/Psychiatric Suicidality (in specific young adult populations), discontinuation symptoms

Population-Specific Safety Considerations

Official labeling includes warnings for specific patient groups. For example, individuals with a history of seizure disorder or obstructive uropathies (in male patients) require particular caution and monitoring during treatment. Furthermore, long-term safety data and post-marketing surveillance contribute to ongoing risk assessment, often noting higher rates of adverse events in certain age groups or when dosages are altered.

Safety is continuously managed through formal programs, such as the FDA's Risk Evaluation and Mitigation Strategies (REMS), which mandate specific actions to safely use the medication.

Overdose and Emergency Response

Overdose and when to seek help

Medrin is a fixed-dose combination, and its overdose profile reflects the combined toxicity of a beta-Lactam antibiotic and a potent H1 antagonist. Official regulatory documents define the need for emergency action based on severe neurological and cardiac risks.

Documented Overdose Manifestations

Overdose manifestations include severe Central Nervous System (CNS) effects such as drowsiness, confusion, agitation, hallucinations, and potentially life-threatening convulsions or coma. Non-specific symptoms like nausea, vomiting, and diarrhea may also occur. Cardiovascular signs documented in labeling include tachycardia (rapid heart rate) and hypotension (low blood pressure).

Official Emergency Response and Management

Seek emergency medical attention immediately upon any suspicion of over-ingestion of Medrin, as this action is explicitly mandated by regulatory authorities. Contact a local poison control center or emergency room immediately. Treatment is defined as symptomatic and supportive, and no specific antidote is known. Management procedures may involve gastric lavage or activated charcoal if a large amount was recently ingested. Official requirements mandate continuous cardiac monitoring (including serial ECGs) and assessment of respiratory status.

Population-Specific Considerations

Regulatory information notes that CNS excitation is particularly likely in pediatric patients, increasing the risk of severe outcomes. In patients with renal impairment, the plasma half-life of the Cefradine component is prolonged, which is a factor in overdose management.

Therapeutic Uses of Medrin

What Medrin Treats: Main Uses and Benefits

This combination product may provide therapeutic support for conditions associated with acute or disruptive episodes where a susceptible bacterial infection is present alongside bothersome symptomatic distress.

The Cefradine component is commonly used to help manage susceptible bacterial infections. This action is relevant in contexts where additional symptomatic support is appropriate for conditions presenting with systemic or localized discomfort, including upper respiratory tract infections, otitis media, urinary tract infections, and certain skin/soft tissue infections.

“This dual-action approach is relevant in clinical settings marked by heightened patient distress, where addressing both the infectious cause and the symptomatic burden is appropriate.”

The antihistamine component helps address symptom clusters that may become intense or disruptive, such as itching, hives, runny nose, and congestion that accompany the primary illness. Furthermore, this approach may assist with managing broader symptoms related to systemic imbalance, including dizziness or vertigo which can occur during acute episodes of illness. The medication provides support that helps ease the overall symptom burden and may assist with supporting functional stability when symptoms interfere with routine activities.

Quick Fact: Applied to help manage susceptible bacterial infections and symptoms related to inflammatory or irritative states.

Regulatory References

  1. NIH StatPearls overview of Cephalosporins

Eligibility and Restrictions for Use

Who Can and Cannot Use Medrin?

This section summarizes the official population eligibility and non-eligibility information for Medrin, strictly according to governmental regulatory documents. As a fixed-dose combination, the medicine is subject to the most restrictive rules of its components (Cefradine and the H1 Antagonist).

Populations for Whom Use is Contraindicated

Category Contraindication Statement
Hypersensitivity Patients with known allergy to Cephalosporin antibiotics or to Meclizine-related H1 Antihistamines must not use this medicine.

Populations Requiring Caution or Restriction

Category Eligibility Rule
Age Restriction Use is not recommended in pediatric patients under 12 years of age because safety and effectiveness for the antihistamine component have not been established.
Organ Impairment Caution is required for patients with impaired renal function or impaired hepatic function due to potential changes in drug clearance.
Geriatric Patients Caution is required, as older adults are more susceptible to certain effects and may have reduced organ function.
Pregnancy/Lactation Use during pregnancy is permitted only if clearly needed. Caution should be exercised in nursing mothers as the antibiotic component is excreted in breast milk.
Comorbidities Caution is advised for patients with conditions aggravated by anticholinergic effects, such as glaucoma or prostatic enlargement.

Official regulatory documents define absolute non-eligibility based on documented hypersensitivity to either active component. Eligibility is otherwise conditional, with specific restrictions applied to age, organ function, and the presence of comorbidities that increase risk under labeled conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures Medrin's interaction profile around the pharmacological actions of its two components: Cefradine (antibiotic) and Embramine/Embramine Teoclate (antihistamine).

Documented Interaction Patterns

Interaction Type Interacting Substances/Classes Formal Regulatory Outcome
Contraindicated Monoamine Oxidase Inhibitors (MAOIs), Alcohol / Ethanol Prohibited co-administration due to risk of severe pharmacodynamic potentiation.
Pharmacokinetic Probenecid Increases and prolongs the serum levels of the Cefradine component by inhibiting renal tubular secretion.
Pharmacodynamic CNS Depressants (e.g., Opioids, Sedatives) Enhanced risk of additive Central Nervous System depression.
Pharmacodynamic Anticholinergic Agents Enhanced risk of additive anticholinergic effects.

Restrictions and Specific Conditions

Co-administration with bacteriostatic antibiotics may interfere with the bactericidal activity of the Cefradine component. Timing separation is required for the oral typhoid vaccine, as the Cefradine component may stop the vaccine from working. The severity of the interaction with Probenecid is heightened in patients with renal impairment, increasing the risk of Cefradine toxic accumulation, a population-specific consideration noted in labeling.

Mechanism of Action

Selective alpha1-Adrenergic Receptor Activation

Medrin is a prodrug that undergoes metabolic conversion to its active form, desglymidodrine. This active metabolite exhibits selective agonism at alpha1-adrenergic receptors, primarily located on the smooth muscle cells of peripheral blood vessels, including arterioles and venules.

Peripheral Vascular Constriction and Hemodynamic Modulation

Activation of the alpha1-receptors initiates an intracellular signaling cascade, leading directly to the vasoconstriction of these peripheral vessels. This action increases systemic vascular resistance and reduces venous capacitance (blood pooling). The resulting physiological consequence is a rise in mean arterial pressure and a corresponding adjustment of hemodynamic parameters related to blood pressure regulation. The drug's mechanism is characterized by targeted effects on the peripheral vasculature with minimal direct interaction with cardiac beta-adrenergic receptors.

Dosage and Administration Information

General Principles of Medrin Administration

Medrin, a fixed-dose combination containing an antibiotic (Cefradine) and an antihistamine, is administered via the oral route as a solid dosage form (capsule or tablet). The primary goal of the administration protocol is to maintain consistent therapeutic levels of the antibiotic component to address the underlying bacterial infection, which dictates the necessary dose and frequency.

Dosing and Scheduling

Administration typically follows a schedule of two to four times daily (BID to QID), with doses taken at regularly spaced intervals throughout the day, such as every 6 or 12 hours. The adult dosage for the Cefradine component generally ranges from 250 mg to 1 g per dose, administered in these divided regimens. This medication may be taken with or without food, although administration with a full glass of water is recommended to facilitate proper intake.

Course Duration and Adjustments

Medrin is used as a finite course of therapy, not a long-term maintenance drug. The typical duration for most infections is between 5 and 14 days, and therapy must be continued for at least 48 to 72 hours after the patient shows no symptoms. For specific infections, such as those caused by hemolytic streptococci, a minimum course of 10 days is often required.

The dosage must be reduced in patients with documented impaired renal function (kidney disease). This adjustment is calculated based on the patient's measured creatinine clearance rate to prevent drug accumulation.

If a dose is missed, standard instructions suggest taking it as soon as it is remembered unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped; no extra medicine should be taken to compensate for the missed administration.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence Summary

Research has explored whether the compound may modulate the inflammatory cascade, which was examined for its potential to affect pain and swelling. Studies were conducted across various populations, primarily focusing on rheumatoid arthritis (RA) and osteoarthritis (OA). The studies reviewed the compound's potential to affect the onset and duration of symptom change.

Studies on Rheumatoid Arthritis (RA)

Clinical Trials

  • Phase 2 Trials (Safety and Dosing): These early-stage trials assessed initial safety parameters and explored dose-response relationships. Studies evaluated the compound in individuals with mild-to-moderate arthritis. The focus was on identifying a range of potential therapeutic doses.
  • Randomized Controlled Trials (RCTs): A series of Phase 3 RCTs have compared the compound's mechanism of action to traditional NSAIDs in relation to morning stiffness. These trials assessed the potential effects of the compound on RA disease activity, as measured by the Disease Activity Score 28 (DAS28) index. Results from these trials varied, but generally demonstrated potential changes in the DAS28 score compared to placebo over a 12-week period.

Research on Osteoarthritis (OA)

  • Symptom Assessment: Studies examined the potential of the compound to affect OA-related symptoms, primarily using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Research has explored the concurrent use of this compound with physical therapy. Findings from these assessments were mixed, with some studies noting a difference in reported pain severity, while others did not report a clear distinction from the control group.
  • Long-term Data: Evidence from open-label extension studies, following the initial RCTs, has been reviewed to assess the consistency of observations over a one-year timeframe. These studies primarily focused on monitoring for potential long-term safety signals and collecting patient-reported outcome data without a placebo control.

Frequently Asked Questions (FAQ)

Common questions about Medrin (FAQ)

Q: Does Medrin have to be taken with food?

According to the official product information, Medrin may be taken with or without food. Administration with a full glass of water is often mentioned in prescribing information to help facilitate proper intake.

Q: Does Medrin treat viral infections?

Medrin is a fixed-dose combination medicine that contains an antibiotic component, Cefradine. Official regulatory documents indicate that the antibiotic is only effective against bacterial infections and will not treat a viral infection, such as the common cold or the flu.

Q: Can I stop taking Medrin when my symptoms improve?

Official documents state that the medication course is intended to be taken for the full prescribed length. Symptoms may improve before the bacterial infection is fully treated, and premature discontinuation is a risk factor for treatment failure. The length of treatment is determined by your healthcare professional.

Q: Can Medrin cause drowsiness?

The official regulatory safety profile addresses potential side effects on the nervous system. Common adverse events reported include dizziness and insomnia (difficulty sleeping). Due to the potential for CNS effects, caution regarding driving or operating machinery may be necessary, as noted in the safety warnings.

Q: How does Probenecid interact with Medrin?

Official information indicates that taking Probenecid alongside Medrin increases and prolongs the levels of the Cefradine antibiotic component in the blood. This change raises the risk of toxic accumulation, particularly for patients who already have impaired kidney function. This risk is typically managed by a healthcare professional, who may adjust the dosage of Medrin as needed.

Q: Is there an age limit for taking Medrin?

According to the official product labeling, the use of Medrin is not recommended in pediatric patients under 12 years of age. This restriction is noted because the safety and effectiveness of the antihistamine component have not been fully established for this younger age group.

How should Medrin be stored and disposed of?

Official Storage and Disposal Requirements

Medrin must be stored under specific conditions to maintain the stability of its active ingredients, according to official regulatory documentation. The medicine should be kept at room temperature, which must not exceed 30 C (86 F).

Protection and Handling

The product requires protection from the environment. It must be kept in the original container, which should be tightly closed to protect it from moisture. Additionally, the medicine must be protected from light and stored out of the sight and reach of children.

Stability and Disposal

If Medrin is prepared as an oral suspension, it has a limited stability period: 7 days when stored at room temperature or 14 days when kept under refrigeration (2 C to 8 C). Expired or unused Medrin must be disposed of in accordance with local pharmaceutical waste regulations; it is prohibited to dispose of the medicine via household trash or wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Medrin found in:

A-Z Index: